Our endoscopy service is over stretched. How can we triage those patients most at risk and reduce the risk of missing cancers in primary care?

Triage with OC-Sensor!

Patients can sometimes present to GPs with anaemia, palpable abdominal or rectal masses which would always require further investigation.  However, the majority of patients present with a range of non-specific symptoms including abdominal pain, weight loss, changes in bowel habits, perianal symptoms and rectal bleeding.  These patients are at ‘low but not no risk’ of bowel cancer and its precursor stages.

The National Institute of Health and Care Excellence (NICE) has revised NG12 to include the use of symptomatic FIT testing to ‘rule in’ patients for the 2-week-wait pathway. More recently Diagnostic Guidance 30 (DG30) has endorsed OC-Sensor, proving it cost effective to ‘rule out’ patients from being referred to secondary care within a cancer pathway.  

FIT in Symptomatic Pathways: Ruling out bowel/colorectal cancer before the use of expensive, unpleasant and risky procedures.

For the health service, colonoscopies are expensive, time consuming and compliance is low.  For the patient, both the colonoscopy procedure and the preparation are unpleasant, disruptive and not without risks.  The vague symptoms presented in primary care could be indicative of a number of diagnoses, including cancer, but more often no organic bowel disease is found at all. >90% of colonoscopies carried out as part of the NG12 pathways for early cancer detection are negative for cancers. This results in a huge waste of resources in secondary care.

With FIT, the whole experience for the patient and the clinician is improved: cancers and pre-cancers can be effectively ruled out with a simple and non-invasive test and the patient can then be reassured (with a 99.7% NPV (Negative Predictive Value))*, and directed down alternative pathways.  For patients with cancer/pre-cancer, the extremely high sensitivity of the test improves early detection rates and if caught early, the prognosis.

Over 25 testing centres across the UK have implemented OC-Sensor as the keystone to their symptomatic FIT service. STPs/CCGs, in line with the NG12 and DG30 guidelines from NICE, are starting to see the benefits of FIT become a reality as early stage cancer detection increases and the referral rate from primary care decreases. Triaging patients with FIT is reducing the burden on secondary care resources and starting to reduce colonoscopy waiting times for patients most in need.

OC-Sensor is approved by NICE (DG30) for use in symptomatic patient testing.

OC-Sensor Pledia

The OC-Sensor Pledia is the latest development from the
OC-Sensor range, including all of the tried and tested ideas and technologies of its predecessors, while retaining the compact and well-tested design.


OC-Sensor iO

The OC-Sensor iO, from the established OC-Sensor series, includes all of the features and technologies of this series, and is distinguished by its particularly compact design.